No increase in risk with dapagliflozin in patients with stage 4 CKD
Jul 21, 2021
Prespecified analysis of RCT shows reduced risk with dapagliflozin versus placebo for composite outcome that included kidney, CV events
Post-acute provider launches comprehensive kidney disease program
By
Alicia Lasek
Aug 05, 2021
Services and therapies will include diabetes management, a full-time respiratory therapist and health coaching with the aim to preserve remaining kidney function. Dialysis will be added as well.
Clinical briefs for Wednesday, May 5
By
Alicia Lasek
May 05, 2021
First case documented of vaccine-induced blood clot treated with a heparin alternative … Researchers urge improvements in kidney failure predictions for chronically ill elders … People 105 or older...
Diabetes med Farxiga gets FDA nod as kidney failure treatment; drug cuts risk by 39 percent
By
Alicia Lasek
May 04, 2021
Farxiga, an SGLT2 inhibitor, was found to reduce the risk of worsening renal function or cardiovascular or renal death by 39% in patients with chronic kidney disease — with and without type 2 diabetes.
New blood pressure target for kidney patients could impact millions, experts say
By
Alicia Lasek
Feb 24, 2021
An estimated 24 million Americans with chronic kidney disease are candidates for intensive blood pressure control under new guidelines from Kidney Disease: Improving Global Outcomes, say Johns Hopkins...
Medicare C-SNP enrollment improves kidney disease outcomes: study
By
Alicia Lasek
Nov 03, 2020
Adults with end-stage renal disease appear to have lower rates of hospitalization and mortality when they enroll in Medicare’s Chronic Condition Special Needs Plans, a new investigation has found.
AHA highlights game-changing benefits of newer diabetes drugs
By
Alicia Lasek
Sep 30, 2020
Newer classes of diabetes drugs reliably protect patients from heart and kidney damage associated with type 2 diabetes and chronic kidney disease, an American Heart Association analysis finds. Increased...
No heart benefits found for chronic kidney disease drug
By
Alicia Lasek
Sep 15, 2020
A seven-year trial shows that the phosphate binder lanthanum carbonate (Fosrenol) does not reduce cardiovascular risk for late-stage renal patients, researchers say.
Diabetes drugs reduce organ failure, mortality risk in chronic kidney disease
By
Alicia Lasek
Sep 03, 2020
New studies show evidence that common glucose-lowering drugs significantly lower the rate of kidney decline and death.
Clinical briefs for Friday, Aug. 28
By
Alicia Lasek
Aug 28, 2020
State’s reopening recommendations eschew social distancing in specific cases … Nutrition guidelines updated in chronic kidney disease … Age-related brain changes may lead to impulsive decisions,...